VERA

Vera Therapeutics, Inc. (VERA) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Balance Sheet Strength

VERA retains a very strong liquidity position with a current ratio of 10.9x and cash ratio of 1.01x.

Leverage remains modest with debt-to-equity at 0.18x and debt-to-assets at 0.14x.

Net debt is effectively negligible at -0.07x EBITDA, supporting balance-sheet resilience.

Profitability Cash Flow Risk

Trailing margins and returns remain deeply negative, with ROA at -75.4%, ROE at -84.1%, and ROIC at -85.8%.

Operating cash flow and free cash flow are both negative, with FCF yield at -16.1% and operating cash flow ratio at -7.0x.

Interest coverage is extremely weak at -36.9x, indicating the business is not currently generating earnings to cover financing costs.

Valuation Support

The stock screens as inexpensive on cash-flow-based multiples, with price-to-free-cash-flow at -6.2x and price-to-operating-cash-flow at -6.2x.

Book-value support is present, with price-to-book at 5.17x and tangible book value per share at 5.68.

Negative earnings and cash flow limit the usefulness of traditional earnings-based valuation metrics.

Operational Efficiency

Asset turnover and revenue efficiency remain weak, with revenue per share at 0 and asset turnover at 0.

The cash conversion cycle is highly distorted at 6106.9 days, reflecting unusual working-capital dynamics.

Payables turnover is negative and days payable outstanding is deeply negative, suggesting the operating data is not yet normalized.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →